Biofrontera Inc. Loss Contingency, Receivable
Biofrontera Inc. (BFRI) had Loss Contingency, Receivable of $6.20 million as of 2022-12-31, per its 8-K filed 2023-10-03.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyReceivable · last filed 2023-10-03
- 2022-12-31: Loss Contingency, Receivable $6.20M.
- 2022-09-30: Loss Contingency, Receivable $5.60M.
- 2022-06-30: Loss Contingency, Receivable $5.60M.
- 2022-03-31: Loss Contingency, Receivable $11.30M.
| Period end | Loss Contingency, Receivable |
|---|---|
| 2022-12-31 | $6.20M 8-K · filed 2023-10-03 |
| 2022-09-30 | $5.60M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.60M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $11.30M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $11.30M 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |